UX-GIP001
Phase 1Biologic
UX-GIP001 is one of 4 biologic programs targeting Temporal Lobe Epilepsy. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Temporal Lobe Epilepsy
#DrugCompanyPhaseTrials
1Lexapro
AbbVieApproved
Feraheme
AAzurity Pharmaceuticals
Approved
NRTX-1001
NNeurona Therapeutics
Phase 3
UX-GIP001
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Temporal Lobe Epilepsy1 trial
Exploratory Study of UX-GIP001 Cell Therapy in Adult Patients With Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT07244328·6 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for UX-GIP001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details